20 "Past Their Prime" Stocks to Dump From Your Portfolio - 19 of 20

Slide 19

Arcellx (NASDAQ:ACLX)

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). Read More

Current Stock Price: $90.96
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $103.08 (13.3% Upside)

Slide 19

Back to 18

Continue to 20

Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

More From MarketBeat

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 19 of 20

Arcellx (NASDAQ:ACLX)

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 19 of 20

Arcellx (NASDAQ:ACLX)

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools